Saúde

Orientação crucial no seu percurso

Com nova e revolucionária tecnologia constantemente a desafiar o status quo, o setor da saúde está a evoluir. Mas num setor baseado em regulamentações, parcerias estratégicas são por vezes a chave para desenvolver negócios de forma bem sucedida. Os nossos assessores, apoiados por equipas sub-sectoriais globais, utilizam o seu conhecimento em M&A, growth equity e ECM, debt advisory e serviços de corporate finance, para encontrar a sua vantagem competitiva, gerir hábitos locais e ajudá-lo a criar a melhor estratégia.

Contactar acessor

Mundialmente

518

transações fechadas em Saúde

Mundialmente

Explore todas as nossas transações no setor

Ir para transações

Decopharma has been acquired by CTT

Saúde | Logística

Decopharma has been acquired by CTT

Decopharma has been acquired by CTT – Correios de Portugal, strengthening its position as a national reference in pharmaceutical logistics solutions. This strategic transaction marks an important step in the consolidation of the specialized logistics sector in Portugal, combining Decopharma’s expertise in healthcare logistics with CTT’s robust infrastructure and growth potential.

Saber mais

Laboratório S. José foi adquirido pela SYNLAB

Serviços de Apoio a Empresas | Saúde

Laboratório S. José foi adquirido pela SYNLAB

Os acionistas privados do Laboratório S. José venderam a empresa à SYNLAB.

Saber mais

Olyos Group has acquired a controlling stake in NewScience

Saúde

Olyos Group has acquired a controlling stake in NewScience

Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.

Saber mais

“Oaklins’ efforts enabled us to join Banook and significantly enhance our impact on respiratory drug development. Together with an outstanding transaction team, we were able to efficiently integrate into the Banook platform, backed by Motion Equity Partners.”

Jan De Backer

CEO, Fluidda NV

Ler mais

Example: https://newsroom-api.pr.co/v1/pressrooms/oaklins/tagged/press_releases?country=AT&includes=featured_images,tags&language=de-AT&limit=3&tags=healthcare 
Ours: https://newsroom-api.pr.co/v1/pressrooms/oaklins/tagged/press_releases?country=PT&includes=featured_images,tags&language=en&limit=1&tags=healthcare

New chapters, global ambitions: mid-market M&A in Q4

QUARTERLY M&A ACTIVITY: In Q4 2025, Oaklins' clients completed 93 transactions across sectors and regions, highlighting how business leaders are using M&A to drive growth, succession and strategic change.

Saber mais